logo

BHVN

Biohaven·NYSE
--
--(--)
--
--(--)
2.78 / 10
Underperform

BHVN's fundamentals score only 2.8/10, indicating challenges in profitability and valuation metrics. Strengths include a healthy inventory turnover ratio (47.88) and solid interest coverage (15.51), but these are offset by a high PB-ROE discrepancy (2.94) and subpar net profit margin. Overall, the company appears defensive, with mixed year-over-year revenue growth (78.62% total operating revenue growth, 92.79% operating revenue growth) that does not fully compensate for other weaknesses.

Fundamental(2.78)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.26
Score3/3
Weight31.29%
1M Return11.03%
Total operating revenue (YoY growth rate %)
Value78.62
Score3/3
Weight2.02%
1M Return0.88%
Inventory turnover ratio
Value47.88
Score2/3
Weight-2.60%
1M Return-1.23%
Profit-MV
Value0.47
Score2/3
Weight25.12%
1M Return8.99%
PB-ROE
Value2.94
Score0/3
Weight8.94%
1M Return3.36%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.51
Score2/3
Weight-2.71%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value92.79
Score2/3
Weight0.23%
1M Return0.10%
Asset-MV
Value-0.51
Score0/3
Weight16.97%
1M Return6.58%
Net profit / Total profit (%)
Value100.18
Score1/3
Weight-3.36%
1M Return-1.59%
Cash-MV
Value-0.07
Score2/3
Weight24.11%
1M Return8.80%
Is BHVN undervalued or overvalued?
  • BHVN scores 2.78/10 on fundamentals and holds a Premium valuation at present. Backed by its -292.05% ROE, 0.00% net margin, -2.01 P/E ratio, -89.70 P/B ratio, and 19.74% earnings growth, these metrics solidify its Underperform investment rating.